Piper Sandler Maintains Overweight on Aclaris Therapeutics, Raises Price Target to $11
Benzinga Newsdesk 6 months ago
NewsPrice TargetAnalyst Ratings
Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.
Piper Sandler analyst Biren Amin maintains Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and raises the price target from $7 to $11.